BioCryst Pharmaceuticals, Inc. (BCRX)
Automate Your Wheel Strategy on BCRX
With Tiblio's Option Bot, you can configure your own wheel strategy including BCRX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol BCRX
- Rev/Share 2.6649
- Book/Share -2.0152
- PB -3.6274
- Debt/Equity -1.7527
- CurrentRatio 2.2492
- ROIC 0.188
- MktCap 1534203209.0
- FreeCF/Share 0.0753
- PFCF 97.3417
- PE -42.8236
- Debt/Assets 1.6162
- DivYield 0
- ROE 0.0786
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 5
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | BCRX | TD Cowen | -- | Buy | -- | $30 | Oct. 15, 2025 |
| Downgrade | BCRX | Evercore ISI | Outperform | In-line | -- | $8 | Oct. 1, 2025 |
| Initiation | BCRX | Cantor Fitzgerald | -- | Overweight | -- | $20 | April 29, 2025 |
| Initiation | BCRX | Wedbush | -- | Outperform | -- | $15 | Feb. 25, 2025 |
News
BioCryst Pharmaceuticals (BCRX) Earnings Expected to Grow: Should You Buy?
Published: October 27, 2025 by: Zacks Investment Research
Sentiment: Positive
BioCryst (BCRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Astria Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Astria Therapeutics, Inc. - ATXS
Published: October 17, 2025 by: Business Wire
Sentiment: Neutral
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Astria Therapeutics, Inc. (NasdaqGM: ATXS) to BioCryst Pharmaceuticals, Inc. (NasdaqGS: BCRX). Under the terms of the proposed transaction, shareholders of Astria will receive $8.55 in cash and 0.59 shares of BioCryst common stock for each share of Astria that they own. KSF is seeking to determ.
Read More
BioCryst Pharmaceuticals, Inc. (BCRX) M&A Call Transcript
Published: October 14, 2025 by: Seeking Alpha
Sentiment: Neutral
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX ) M&A Call October 14, 2025 8:00 AM EDT Company Participants Nick Wilder Jon Stonehouse - CEO & Executive Director Charles Gayer - President & Chief Commercial Officer Babar Ghias - CFO & Head of Corporate Development Conference Call Participants Stacy Ku - TD Cowen, Research Division Laura Chico - Wedbush Securities Inc., Research Division Steven Seedhouse - Cantor Fitzgerald & Co., Research Division Brian Abrahams - RBC Capital Markets, Research Division Jonathan Wolleben - Citizens JMP Securities, LLC, Research Division Huidong Wang - Barclays Bank PLC, Research Division Maurice Raycroft - Jefferies LLC, Research Division …
Read More
BioCryst Says Astria Therapeutics $700 Million Deal Gives 'Perfect Second Product Candidate'
Published: October 14, 2025 by: Benzinga
Sentiment: Positive
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) on Tuesday agreed to acquire Astria Therapeutics, Inc. (NASDAQ:ATXS) for a mix of cash and stock.
Read More
Is the Options Market Predicting a Spike in BioCryst Pharmaceuticals Stock?
Published: October 14, 2025 by: Zacks Investment Research
Sentiment: Neutral
Investors need to pay close attention to BCRX stock based on the movements in the options market lately.
Read More
Down 14.3% in 4 Weeks, Here's Why BioCryst (BCRX) Looks Ripe for a Turnaround
Published: October 07, 2025 by: Zacks Investment Research
Sentiment: Positive
BioCryst (BCRX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Read More
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Published: October 03, 2025 by: GlobeNewsWire
Sentiment: Neutral
RESEARCH TRIANGLE PARK, N.C., Oct. 03, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted eight newly-hired employees stock options to purchase an aggregate of 115,000 shares, and restricted stock units (RSUs) covering an aggregate of 91,450 shares, of BioCryst common stock. The options and RSUs were granted as of October 1, 2025, as inducements material to each employee entering into employment with BioCryst. The options and RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
Read More
BioCryst Announces Departure of Dr. Helen Thackray
Published: August 11, 2025 by: GlobeNewsWire
Sentiment: Neutral
RESEARCH TRIANGLE PARK, N.C., Aug. 11, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that Dr. Helen Thackray, chief research and development officer, will leave the company September 1, 2025 and transition into an advisory role through the end of the year.
Read More
BioCryst Pharmaceuticals, Inc. (BCRX) Q2 2025 Earnings Call Transcript
Published: August 04, 2025 by: Seeking Alpha
Sentiment: Neutral
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX ) Q2 2025 Earnings Conference Call August 4, 2025 8:30 AM ET Company Participants Babar Ghias - CFO & Head of Corporate Development Charles K. Gayer - President Donald S.
Read More
BioCryst Pharmaceuticals (BCRX) Surpasses Q2 Earnings and Revenue Estimates
Published: August 04, 2025 by: Zacks Investment Research
Sentiment: Positive
BioCryst Pharmaceuticals (BCRX) came out with quarterly earnings of $0.15 per share, beating the Zacks Consensus Estimate of $0.03 per share. This compares to a loss of $0.06 per share a year ago.
Read More
BioCryst Pharmaceuticals Before Q2 Earnings: How to Play the Stock
Published: July 31, 2025 by: Zacks Investment Research
Sentiment: Positive
BCRX gears up for Q2 results with Orladeyo growth in focus, but 2025 EPS forecasts dip as investors eye pipeline progress.
Read More
BioCryst Pharmaceuticals (BCRX) Reports Next Week: Wall Street Expects Earnings Growth
Published: July 28, 2025 by: Zacks Investment Research
Sentiment: Positive
BioCryst (BCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
BioCryst to Report Second Quarter 2025 Financial Results on August 4
Published: July 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
RESEARCH TRIANGLE PARK, N.C., July 21, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its second quarter 2025 financial results on Monday, August 4, 2025.
Read More
Is BioCryst Pharmaceuticals (BCRX) Outperforming Other Medical Stocks This Year?
Published: July 07, 2025 by: Zacks Investment Research
Sentiment: Positive
Here is how BioCryst Pharmaceuticals (BCRX) and Cardinal Health (CAH) have performed compared to their sector so far this year.
Read More
BioCryst (BCRX) Upgraded to Strong Buy: What Does It Mean for the Stock?
Published: June 25, 2025 by: Zacks Investment Research
Sentiment: Positive
BioCryst (BCRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Read More
BioCryst Achieves Reimbursement for ORLADEYO Across all Major European Countries
Published: June 06, 2025 by: GlobeNewsWire
Sentiment: Neutral
RESEARCH TRIANGLE PARK, N.C., June 06, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that, following a positive recommendation from the Zorginstituut Nederland, ORLADEYO® (berotralstat) has been approved for the routine prevention of hereditary angioedema (HAE) attacks in patients aged 12 years and older.
Read More
BioCryst Pharmaceuticals (BCRX) is a Great Momentum Stock: Should You Buy?
Published: June 04, 2025 by: Zacks Investment Research
Sentiment: Positive
Does BioCryst Pharmaceuticals (BCRX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Read More
Best Momentum Stock to Buy for June 4th
Published: June 04, 2025 by: Zacks Investment Research
Sentiment: Positive
BCRX made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on June 4, 2025.
Read More
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Published: June 03, 2025 by: GlobeNewsWire
Sentiment: Neutral
RESEARCH TRIANGLE PARK, N.C., June 03, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted seven newly-hired employees restricted stock units (RSUs) covering an aggregate of 47,250 shares of BioCryst common stock. The RSUs were granted as of June 2, 2025, as inducements material to each employee entering into employment with BioCryst. The RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
Read More
BioCryst to Present New Data at 2025 Meeting of the European Academy of Allergy and Clinical Immunology
Published: June 02, 2025 by: GlobeNewsWire
Sentiment: Neutral
RESEARCH TRIANGLE PARK, N.C., June 02, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that new data on oral, once-daily ORLADEYO® (berotralstat) for the prophylactic treatment of hereditary angioedema (HAE) will be presented at the European Academy of Allergy and Clinical Immunology (EAACI) meeting in Glasgow, United Kingdom, from June 13 to 16, 2025.
Read More
Wall Street Analysts Believe BioCryst (BCRX) Could Rally 55.81%: Here's is How to Trade
Published: May 26, 2025 by: Zacks Investment Research
Sentiment: Positive
The mean of analysts' price targets for BioCryst (BCRX) points to a 55.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Read More
BioCryst Presents New Real-world Evidence Showing Significant and Sustained Reductions in HAE Attack Rates in Adolescents and People with Severe HAE Following Initiation of ORLADEYO® (berotralstat)
Published: May 16, 2025 by: GlobeNewsWire
Sentiment: Neutral
RESEARCH TRIANGLE PARK, N.C., May 16, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new real-world evidence on the use of oral, once-daily ORLADEYO® (berotralstat) in adolescents and people with severe HAE showing significant and sustained reductions in HAE attack rates through 18 months of follow-up after beginning treatment with ORLADEYO in both patient populations.
Read More
Best Momentum Stocks to Buy for May 9th
Published: May 09, 2025 by: Zacks Investment Research
Sentiment: Positive
BCRX, WYY and RMBS made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on May 9, 2025.
Read More
New Strong Buy Stocks for May 9th
Published: May 09, 2025 by: Zacks Investment Research
Sentiment: Positive
CBNA, FMS, BNTGY, WYY and BCRX have been added to the Zacks Rank #1 (Strong Buy) List on May 9, 2025.
Read More
Why BioCryst (BCRX) Might be Well Poised for a Surge
Published: May 08, 2025 by: Zacks Investment Research
Sentiment: Positive
BioCryst (BCRX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Read More
What Makes BioCryst Pharmaceuticals (BCRX) a Strong Momentum Stock: Buy Now?
Published: May 08, 2025 by: Zacks Investment Research
Sentiment: Positive
Does BioCryst Pharmaceuticals (BCRX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Read More
Does BioCryst (BCRX) Have the Potential to Rally 61.21% as Wall Street Analysts Expect?
Published: May 08, 2025 by: Zacks Investment Research
Sentiment: Positive
The mean of analysts' price targets for BioCryst (BCRX) points to a 61.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Read More
BioCryst: Strong Opportunity For A Double With A Proven Therapy
Published: May 05, 2025 by: Seeking Alpha
Sentiment: Positive
BioCryst Pharmaceuticals' flagship product ORLADEYO shows remarkable growth, maintaining a persistent upward trajectory since its launch in 2020, and is expected to continue into 2025. Despite heavy reliance on ORLADEYO, BCRX stock remains a "Buy" due to its strong market presence and growth potential in the hereditary angioedema therapy market. The 10-K report highlights competition, including late-stage therapies and an upcoming PDUFA date for KalVista's sebetralstat, which could impact market dynamics.
Read More
BioCryst Pharmaceuticals, Inc. (BCRX) Q1 2025 Earnings Call Transcript
Published: May 05, 2025 by: Seeking Alpha
Sentiment: Neutral
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX ) Q1 2025 Earnings Conference Call May 5, 2025 8:30 AM ET Company Participants John Bluth - Chief Communications Officer Jon Stonehouse - CEO Charlie Gayer - Chief Commercial Officer Helen Thackray - Chief R&D Officer Conference Call Participants Steven Seedhouse - Cantor Maury Raycroft - Jefferies Jessica Fye - JP Morgan Stacy Ku - TD Cowen Gena Wang - Barclays Laura Chico - Wedbush Securities Liisa Bayko - Evercore ISI Serge Belanger - Needham & Co. Jonathan Wolleben - Citizens JMP Operator Good day, and welcome to the BioCryst First Quarter 2025 Earnings Conference Call. …
Read More
BioCryst Pharmaceuticals (BCRX) Reports Break-Even Earnings for Q1
Published: May 05, 2025 by: Zacks Investment Research
Sentiment: Neutral
BioCryst Pharmaceuticals (BCRX) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to loss of $0.17 per share a year ago.
Read More
About BioCryst Pharmaceuticals, Inc. (BCRX)
- IPO Date 1994-03-04
- Website https://www.biocryst.com
- Industry Biotechnology
- CEO Jon P. Stonehouse
- Employees 580